IDH突变型胶质瘤患者的衰弱状态:来自高容量肿瘤中心的经验
该研究在2007至2021年间纳入本机构136例IDH突变型胶质瘤患者,以mFI-5≥1和CCI≥3定义高衰弱,评估衰弱对30天再入院和总生存的影响。高衰弱与更高BMI、更多神经功能缺损和更大手术年龄相关;CCI和mFI-5与30天再入院及OS无显著关联,但在新诊断肿瘤患者中高mFI-5与调整后死亡风险升高相关。作者认为需更大队列进一步研究衰弱以改善神经外科治疗后的预后判断。
要点
- 136例IDH突变型胶质瘤中52例(38%)为高衰弱:CCI≥3者18例,mFI-5≥1者34例。
- 高衰弱与更高BMI(CCI组30.2、mFI-5组30.1 kg/m2)、更多神经功能缺损(CCI组61%、mFI-5组56%)及更大手术年龄(CCI组63岁、mFI-5组48岁)相关。
- 新诊断肿瘤患者中高mFI-5者调整后死亡风险为低mFI-5者的6.79倍(p=.049)。
核心结论
- CCI和mFI-5与30天再入院及OS均无显著关联,但在非复发肿瘤患者中mFI-5与OS存在显著关联。
- 作者认为需更大队列进一步研究衰弱,以改善神经外科治疗后的预后判断。
研究设计与样本
- 单机构研究,2007至2021年间纳入136例IDH突变型胶质瘤患者。
- 以mFI-5评分≥1和CCI≥3定义高衰弱,记录患者及肿瘤特征,采用逻辑回归和Kaplan-Meier曲线分析30天再入院和OS。
主要发现
- 136例中52例(38%)为高衰弱:CCI≥3者18例,mFI-5≥1者34例。
- 高衰弱与更高BMI(CCI组30.2、mFI-5组30.1 kg/m2)、更多神经功能缺损(CCI组61%、mFI-5组56%)及更大手术年龄(CCI组63岁、mFI-5组48岁)相关。
- 30天内再入院8例(5.9%);逻辑回归显示高衰弱与低衰弱组30天再入院率无显著差异(CCI:p=0.30,mFI-5:p=0.62),中位OS亦无显著差异。
- 本机构收治的新诊断肿瘤患者中,高mFI-5者调整后死亡风险为低mFI-5者的6.79倍(p=.049)。
局限性
- 原文未报告局限性,但作者在结论中提出需更大队列进一步研究衰弱。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Gliomas are increasingly diagnosed in an aging population, with treatment outcomes influenced by factors like tumor genetics and patient frailty. This study focused on IDH-mutant gliomas and assessed how frailty affects 30-day readmission and overall survival (OS). We aimed to address a gap in understanding the impact of frailty on this specific glioma subtype. METHODS: 136 patients with an IDH-mutant glioma between 2007 and 2021 were identified at our institution. High frailty was classified by scores ≥ 1 on the 5-factor modified frailty index (mFI-5) and ≥ 3 on the Charlson Comorbidity Index (CCI). Patient and tumor characteristics including age, sex, race, Karnofsky Performance Status (KPS), Body Mass Index (BMI), tumor type and location, type of operation, and therapy course were recorded. Outcomes measured included 30-day readmission and overall survival (OS). Analysis was conducted utilizing logistic regression and Kaplan-Meier curves. RESULTS: Of the 136 patients, 52 (38%) had high frailty: 18 with CCI ≥ 3, 34 with mFI-5 ≥ 1. High frailty correlated with increased BMI (CCI: 30.2, mFI-5: 30.1 kg/m2), more neurological deficits (CCI: 61%, mFI-5: 56%), and older age at surgery (CCI: 63, mFI-5: 48 years). Hospital readmission within 30 days occurred in 8 (5.9%) patients. Logistic regression indicated no significant difference in 30-day readmission rates (CCI: p = 0.30, mFI-5: p = 0.62) or median OS between high and low frailty groups. However, patients treated at our institution with newly diagnosed tumors with high mFI-5 had a 6.79 times higher adjusted death hazard than those with low mFI-5 (p = .049). CONCLUSION: Our analysis revealed that CCI and mFI-5 were not significantly associated with 30-day nor OS. However, in patients with non-recurrent tumors, there was a significant association of mFI-5 with OS. Further study of frailty with larger cohorts is warranted to enhance prognostication of outcome after neurosurgical treatment.
引用
- Bray DP, Stubbs NM, Chow J, et al. Frailty in patients with IDH-mutant gliomas: experience from a high-volume tumor center. J Neurooncol. 2024. PMID: 38833032. doi:10.1007/s11060-024-04685-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。